Shire PLC (NASDAQ:SHPG) – Investment analysts at William Blair reduced their FY2017 earnings per share (EPS) estimates for Shire PLC in a note issued to investors on Tuesday. William Blair analyst T. Lugo now forecasts that the biopharmaceutical company will earn $14.63 per share for the year, down from their previous forecast of $14.85. William Blair also issued estimates for Shire PLC’s FY2018 earnings at $16.44 EPS and FY2020 earnings at $19.99 EPS.

Several other equities research analysts also recently weighed in on the stock. Cantor Fitzgerald set a $222.00 price objective on shares of Shire PLC and gave the stock a “buy” rating in a report on Saturday, July 1st. Stifel Nicolaus reaffirmed a “buy” rating and issued a $245.00 price objective on shares of Shire PLC in a report on Wednesday, July 12th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $210.00 price objective on shares of Shire PLC in a report on Thursday, July 13th. BidaskClub downgraded shares of Shire PLC from a “sell” rating to a “strong sell” rating in a report on Wednesday. Finally, BTIG Research reaffirmed a “buy” rating and issued a $242.00 price objective on shares of Shire PLC in a report on Monday. Two analysts have rated the stock with a sell rating, seven have given a hold rating and sixteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $227.45.

WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/07/20/shire-plc-nasdaqshpg-expected-to-earn-fy2017-earnings-of-14-63-per-share.html.

Shire PLC (NASDAQ SHPG) opened at 162.79 on Thursday. Shire PLC has a 12 month low of $158.88 and a 12 month high of $209.22.

Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 EPS for the quarter, topping the Zacks’ consensus estimate of $3.22 by $0.41. The company had revenue of $3.57 billion during the quarter. Shire PLC had a net margin of 2.14% and a return on equity of 13.05%. The firm’s quarterly revenue was up 109.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.12 EPS.

Several large investors have recently made changes to their positions in the stock. BB&T Corp boosted its stake in shares of Shire PLC by 28.7% in the second quarter. BB&T Corp now owns 9,296 shares of the biopharmaceutical company’s stock valued at $1,536,000 after buying an additional 2,075 shares during the last quarter. US Bancorp DE boosted its stake in shares of Shire PLC by 20.7% in the second quarter. US Bancorp DE now owns 45,022 shares of the biopharmaceutical company’s stock valued at $7,440,000 after buying an additional 7,730 shares during the last quarter. Inspirion Wealth Advisors LLC boosted its stake in shares of Shire PLC by 0.4% in the second quarter. Inspirion Wealth Advisors LLC now owns 1,944 shares of the biopharmaceutical company’s stock valued at $321,000 after buying an additional 8 shares during the last quarter. Aperio Group LLC boosted its stake in shares of Shire PLC by 2.2% in the second quarter. Aperio Group LLC now owns 88,045 shares of the biopharmaceutical company’s stock valued at $14,551,000 after buying an additional 1,906 shares during the last quarter. Finally, TNB Financial boosted its stake in shares of Shire PLC by 5.9% in the second quarter. TNB Financial now owns 21,204 shares of the biopharmaceutical company’s stock valued at $3,505,000 after buying an additional 1,188 shares during the last quarter. 21.06% of the stock is owned by institutional investors and hedge funds.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Earnings History and Estimates for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.